Siegfried Holding AG (SFZN.SW) SIX
Currency In CHF
- General
- Statistics
- Historical Data
- Profile
- Financials
Siegfried Holding AG
Address
Untere Bruehlstrasse 4
Zofingen, AG 4800
Switzerland
Phone
41 62 746 1111
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
3891
First IPO Date
April 03, 1995
Key Executives
| Name | Title | Pay | Year Born |
| Marcel Imwinkelried | Chief Executive Officer & Chief Operating Officer Drug Products ad interim | 1.66M | 1967 |
| Reto Suter | Chief Financial Officer | 0 | 1971 |
| Tania Micki | Chief Financial Officer | 0 | 1971 |
| Peter Freisler | Chief Business Officer | 0 | N/A |
| Beatrice Harder | Head Regulatory Affairs - Site Zofingen | 0 | N/A |
| Luca Dalla Torre | Chief Legal & Sustainability Officer | 0 | N/A |
| Enno Schweinberger | Head Global Quality Management DS - Zofingen | 0 | N/A |
| Peter Stierli | Head of Corporate Communications | 0 | N/A |
| Olesia Silanteva | Chief Human Resources Officer | 0 | 1982 |
| Stefan Randl | Interim Chief Operating Officer Drug Substances & Chief Scientific Officer | 0 | N/A |
| Florent Trouillet | Head Corporate Quality Systems - Global Quality Systems | 0 | N/A |
| John Jones | Head of Operations - Malta | 0 | N/A |
Description
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
